Novo Nordisk 

Compound Sharing

Novo Nordisk 

Compound Sharing


Partial glucagonR agonist

Amount per vial
1000 nmol
Glucagon is s a 29 amino acid residue peptide hormone produced by the alpha-cells in the pancreas. Together with insulin it regulates blood glucose levels. It stimulates release of glucose from the liver at low blood glucose levels by increasing gluconeogenesis and glycogenolysis, and by suppressing glycolysis. Glucagon is used to treat insulin-induced severe hypoglycemia. This compound is a partial glucagon receptor agonist. 

MW (Da)3900.13482.7
pI (calculated)3.76.4
Sequence substitutions (compared to rerefence) desHis1, Glu9, Lys24(4xgGlu-Ac)-
Extinction coefficient (calculated, 280 nm)84808840

2D sketch of the structure of NNC9204-1702. Compared to native glucagon, the N-terminal histine has been removed, a glutamic acid is present in position 9 and Ac-4xgGlu has been attached to the lysine in position 24.
2D sketch of the sequence of native glucagon.

Please see the Zhang et al. 2018 reference listed in the reference section for further details.

Glucagon receptorCompoundIC50 (nM)
Wild typeGlucagon37.2

Native glucagon is available as a reference compound to NNC9204-1702. Please indicate in the 'Purpose' field when you order NNC9204-1702 if you would like to have native glucagon included in your shipment

The freeze-dried material should be stored at -18C. NNC9204-1702 can be dosed in vivo in a formulation vehicle containing 50mM sodium phosphate, 145mM propylene glycol, (0.007% polysorbate 20 if concentrations are so low that adsorption to vials may affect the concentration), pH 7.4. Stability in aqueous media is poor thus formulations should be used fresh. For in vitro it is recommended to dissolve human glucagon in 100% DMSO and keep at max 5C. Peptides and proteins have a tendency to adhere to glass and plastic surfaces. This may at low concentration impact the actual amount in solution. To minimize this unspecific adherence, adding detergents or inert proteins like e.g., ovalbumin or other serum albumins to the solution can minimize this phenomenon. In case albumins are added to peptide/protein solutions, ensure that the albumins are free of any proteases.

Zhang H et al.
Structure of the glucagon receptor in complex with a glucagon analogue
Nature. 2018;553(7686):106-110